Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima lineaCompanies: Johnson & JohnsonJohnson & Johnson, leader mondiale nel campo del trattamento del mieloma multiplo, ha annunciato oggi nuovi dati provenienti dallo studio di Fase 3 MajesTEC-3, che dimostrano un controllo della malattia e una sopravvivenza duraturi con TECVAYLI® (teclistamab) in associazione con daratumumab nei pazienti affetti da mieloma multiplo recidivante o refrattario (RRMM) che avevano precedentemente ricevuto da 1 a 3 linee di terapia.
- Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definierenCompanies: Johnson & JohnsonJohnson & Johnson, ein weltweit führendes Unternehmen im Bereich des multiplen Myeloms, gab heute neue Daten aus der Phase III-Studie MajesTEC-3 bekannt, die eine anhaltende Krankheitskontrolle und Überlebenszeit unter TECVAYLI® (teclistamab) in Kombination mit daratumumab bei Patienten mit rezidiviertem oder refraktärem multiplem Myelom (RRMM) belegen, die zuvor 1 bis 3 Therapielinien erhalten hatten.
- Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitementCompanies: Johnson & JohnsonBEERSE, Belgique, 28 sept. 2026 -- Johnson & Johnson, leader mondial dans le domaine du myélome multiple, a annoncé aujourd’hui de nouvelles données issues de l’étude de Phase 3 MajesTEC-3, mettant en évidence un contrôle durable de la maladie et une survie prolongée avec TECVAYLI® (teclistamab) associé au daratumumab chez des patients atteints d’un myélome multiple en rechute ou réfractaire (MMRR) ayant reçu 1 à 3 lignes de traitement antérieures.
- Johnson & JohnsonRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026Companies: Johnson & JohnsonLow rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival...
- Johnson & JohnsonJohnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerCompanies: Johnson & JohnsonRYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026...
- Johnson & JohnsonJohnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsCompanies: Johnson & JohnsonNEW BRUNSWICK, N.J., August 31, 2026--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J.
- Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution ChannelCompanies: AbbVieAmgenJohnson & JohnsonNovartisThe global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials, regulatory approvals and pharmaceutical R&D, despite high treatment costs and limited access in developing regions.
- Johnson & JohnsonFDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsCompanies: Johnson & JohnsonIMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood...
- Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & JohnsonCompanies: Johnson & JohnsonDALLAS, August 24, 2026--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $10 million jury verdict in a mesothelioma case brought on behalf of the family of Lynne Roy, a Louisiana woman who died in 2020 after developing the deadly lung disease mesothelioma following decades of exposure to talc products.